PI3K

[Nature Communications] Scientists found that PIK3CA-mutant ER+ breast cancers exhibited increased INPP4B mRNA and protein expression and INPP4B increased the proliferation and tumor growth of PIK3CA-mutant ER+ breast cancer cells, despite suppression of AKT signaling.

[Cancer Research] Oral administration of an antibiotic mixture in prostate cancer (PCa)-bearing mice fed a high-fat diet containing a large proportion of lard drastically altered the composition of the gut microbiota including Rikenellaceae and Clostridiales, inhibited PCa cell proliferation, and reduced prostate Igf1 expression and circulating IGF-1 levels.

[TG Therapeutics, Inc. (Globe Newswire, Inc.)] TG Therapeutics, Inc. announced that the FDA has accepted the Biologics License Application for Ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ®, their inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

[Cancer Gene Therapy] Scientists identified the mechanism of lncRNA OIP5-AS1 in colon cancer (CC) development. OIP5-AS1 expression pattern in CC tissues and cells was detected and the relation between OIP5-AS1 level and CC prognosis was analyzed.

[Molecular Medicine Reports] Scientists investigated the effects of the PI3K inhibitor LY‑294002 and AKT inhibitor MK2206 on the chemosensitivity of oxaliplatin‑resistant liver cancer cells and the molecular mechanism involved.

[Frontiers in Immunology] Scientists used multiphoton intravital microscopy to examine the role of RGD-binding integrins and signaling through phosphoinositide 3-kinase P110δ in intradermal Treg migration in resting and inflamed skin.